Tango Therapeutics (TNGX) Fundamental Analysis: Revenue, Earnings & Valuation

5.94 / 10

Netural

Fundamental analysis rates the company neutral (5.9/10). Positive factors include PB‑ROE, Revenue‑MV, Cash‑MV and strong inventory turnover, while fixed‑asset turnover and YoY revenue growth show weakness. Overall, fundamentals are modest, suggesting a guarded investment stance.

Analysis Checks(9/10)

Revenue-MV

Value-0.11

Score2/3

Weight17.87%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value48.29

Score2/3

Weight-1.76%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight14.57%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.32%

1M Return1.69%

PB-ROE

Value1.34

Score2/3

Weight13.79%

1M Return6.97%

Income tax / Total profit (%)

Value-0.00

Score2/3

Weight1.95%

1M Return1.04%

Fixed assets turnover ratio

Value1.39

Score1/3

Weight-2.03%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight8.43%

1M Return4.32%

Asset-MV

Value-0.55

Score3/3

Weight30.92%

1M Return11.84%

Cash-MV

Value0.02

Score2/3

Weight12.94%

1M Return5.94%

Is TNGX undervalued or overvalued?

TNGX scores 5.94/10 on fundamentals and holds a Fair valuation at present. Backed by its -37.23% ROE, -162.85% net margin, -27.05 P/E ratio, 7.94 P/B ratio, and 26.89% earnings growth, these metrics solidify its Netural investment rating.